CD4 and neoplasm: We compared the immune repertoire between treatment groups by assessing CD8+ T cells, CD4 + FOXP3+ Tregs, the CD8+ T cell to Treg ratio, CD45 + CD11b + CD103+ dendritic cells, and CD44highCD62Llow effector memory CD8+ and CD4+ T cells in spleen samples from 4T1-luc tumor-bearing mice (Figure 2).